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This study examines the ability of nonclinical adverse event observations to predict human clinical
adverse events observed in drug development programs. In addition it examines the relationship
between nonclinical and clinical adverse event observations to drug withdrawal and proposes a model
to predict drug withdrawal based on these observations. These analyses provide risk assessments useful
for both planning patient safety programs, as well as a statistical framework for assessing the future
success of drug programs based on nonclinical and clinical observations.
Bayesian analyses were undertaken to investigate the connection between nonclinical adverse event
observations and observations of that same event in clinical trial for a large set of approved drugs. We
employed the same statistical methods used to evaluate the efﬁcacy of diagnostic tests to evaluate the
ability of nonclinical studies to predict adverse events in clinical studies, and adverse events in both to
predict drug withdrawal. We ﬁnd that some nonclinical observations suggest higher risk for observing
the same adverse event in clinical studies, particularly arrhythmias, QT prolongation, and abnormal hep-
atic function. However the lack of these events in nonclinical studies is found to not be a good predictor of
safety in humans. Some nonclinical and clinical observations appear to be associated with high risk of
drug withdrawal from market, especially arrhythmia and hepatic necrosis. We use the method to esti-
mate the overall risk of drug withdrawal frommarket using the product of the risks from each nonclinical
and clinical observation to create a risk proﬁle.
 2015 Elsevier Inc. All rights reserved.1. Introduction
Nonclinical animal models have long been accepted as a means
to examine both the efﬁcacy and toxicity of drugs before
administration to humans. The motivation has always been to
reduce risk to humans by observing the outcomes in animals [1].
The desire for animal testing for toxicity was increased after public
tragedies of the ‘‘Lash-Lure’’ case in which aniline eyelash dyes
caused blindness, the toxicity associated with the formulation of
sulfanilamide with ethylene glycol, and the teratogenic effects of
thalidomide [2–4].
Animal models for toxicity have been shown to correctly repre-
sent human toxicities in many cases [5]. However there are rela-
tively few statistical studies evaluating the concordance of
nonclinical and clinical observations [6]. The study of 30 com-
pounds in various species by Goldsmith et al found that animals
well predicted the maximum tolerated dosages for clinical trials
[7]. Fletcher examined 45 compounds and found a lowconcordance between animal and human adverse events [8]. The
current canonical work in animal–human concordance for toxicity
is the Olson study which examined animal and human toxicity of
150 compounds from a variety of therapeutic areas. In that work,
the overall true positive animal–human concordance rate was 7%
for rodent only, 36% for combination of rodent and non-rodent,
27% for single non-rodent species, and 70% for observation in any
species [9]. Several other studies have been published since then
with generally similar results [10–13]. However, the majority of
the evidence for the efﬁcacy of animal studies is based on true
positives, with limited analysis of the false positives and false
negatives [14,15].
Evaluation of the ability of animal models to predict human
responses and toxicities is critical now that there are increasing
pressures to reduce animal testing in favor of in-vitro and com-
putational predictive methods [16]. In this work we compared data
for drugs that have matched nonclinical and clinical data presented
in FDA and EMEA submissions and analyze the results to measure
the concordance between nonclinical and clinical adverse event
observations. The human–animal concordance is measured using
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efﬁcacy of diagnostic tests. In addition, we study the relationship
between the events and eventual drug withdrawal to look for
observations that are statistically correlated to drug failure.nonclinical observation a c 
no nonclinical
observation b d 
cells contain count of drugs in each category for the 
given class of adverse events
Fig. 2. 2  2 Contingency table used for statistical analysis.2. Methods
2.1. Data sources
The PharmaPendium database from Elsevier was used to sum-
marize the adverse events each selected MedDRA adverse classes
reported for each drug, as shown in Fig. 1 [17,18].
PharmaPendium contains data for 3815 drugs or drug for-
mulations. The data is mined from FDA and EMEA documents
released in connection with drug approval, and is supplemented
by data from Mosby’s Drug Consult and Meyler’s Side Effects of
Drugs [19,20]. Of the drugs that appear in the database, 102 have
been withdrawn from the market or relabeled, providing a limited
set of failure results for statistical analysis. In this case each
approved formulation was considered separately since it is possi-
ble for drug combinations to have different adverse events than
the drugs alone. Fig. 1 shows an example of the raw data from
PharmaPendium that summarizes the number of times arrhyth-
mias were reported for each drug. Each value is linked to full
reports of each observation, linked to the original submission
documents. Post-marketing adverse event reports were not used
in this study; only those reported in controlled clinical studies
were used.
In order to eliminate dependence on the number of submissions
and clinical studies of each drug for various indications, each value
in the table was translated to an indicator variable of 1, if there was
an observation of an event in the category, and 0 if there were
none. This was done to avoid using the raw counts which may be
dependent on the number of studies performed for a particular
drug. The indicator denotes that the drug is reported at least once
to cause the effect. These indicator values were then used for the
analyses.Fig. 1. PharmaPendium sum2.2. Bayesian statistics
Bayesian statistics were used with a 2 by 2 contingency table to
measure the relationship between two sets of observations – the
relationships between nonclinical and clinical observations for
adverse events or adverse event categories, and separately, com-
bined nonclinical/clinical observations with drug withdrawal (see
Fig. 2). We treat the nonclinical observation as a diagnostic test
for the clinical observation and use the statistical methods devel-
oped for evaluation of the efﬁcacy of diagnostic tests. The same
analysis is applied to measure the relationship between adverse
event observation and drug withdrawal.
The values in the 2 by 2 contingency table, which are counts of
number of compounds in each of the four categories for a given
biomedical observation or MedDRA class of observations, were
generated as follows:
(a) Count of drugs for which the event was observed in both
nonclinical and clinical studies – true positives.mary of adverse events.
clinical 
observation
no clinical 
observation
nonclinical observation 55 14
no nonclinical
observation 946 2800
cells contain count of drugs in each category
Fig. 3. The 2  2 contingency table used to compute likelihood ratios for observing
an arrhythmia in clinical study if observed in a nonclinical study.
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but not nonclinical – false negatives.
(c) Count of drugs for the event was observed in nonclinical
studies but not clinical studies – false positives.
(d) Count of drugs without the adverse event observation in
either nonclinical or clinical studies – true negatives.
In this study we use likelihood ratios to express the statistical
connection between nonclinical and clinical observations [21].
The likelihood ratio has the advantage that it is independent from
the prevalence (Bayesian prior probability) for each observation so
that it is more comparable across different adverse events than the
conditional probability or positive predictive value [22]. This is
important because the overall prevalence of adverse events is rela-
tively low, which results in a low sensitivity metric, as well as low
positive predictive value. The likelihood ratio computed here
represents the change in clinical risk when the adverse event is
observed in a nonclinical study.
The sensitivity, a/(a + b), is the ability of the nonclinical adverse
even observation to predict that the adverse event will be observed
clinically. The speciﬁcity, d/(c + d), is the ability of the nonclinical
result to predict that the adverse event will not be observed in a
clinical study.
The positive likelihood ratio (LR+) is computed from the
sensitivity and the speciﬁcity. The positive likelihood is sensitiv-
ity/(1  speciﬁcity), and the negative likelihood is (1  sensitiv-
ity)/speciﬁcity. Positive likelihood ratios greater than 1.0 indicate
a higher likelihood that the clinical observation will be made if
the nonclinical observation is made. The negative likelihood
(LR) refers to the likelihood that there will be no clinical observa-
tion if no nonclinical observation is made. LR values close to 0.0
suggest that the lack of nonclinical observation will predict lack
of clinical observation. A value close to 1.0 for either LR+ or LR
suggests that there is no change in risk for either an observation
or lack of an observation. A subjective explanation of the signiﬁ-
cance of the values is given in Table 1 [22]. The p-values for the
relationships in the 2  2 tables were computed using Fisher’s
exact test implemented in R [23]. The Fisher’s test is considered
better than the chi-square test of signiﬁcance for the unbalanced
data tables in this study. Only relationships with p-values less than
0.05 were retained for this work, with the majority being orders of
magnitude less than this value.
Fig. 3 shows example data for the adverse event ‘‘arrhythmia’’.
There were 55 drugs for which arrhythmia was reported in non-
clinical and clinical studies, 14 for which there was arrhythmia
in a nonclinical study but not in a clinical study, and 946 drugs
where there was a clinical observation but no nonclinical observa-
tion. Finally, there are 2800 drugs with no arrhythmia reported in
either study type. The total sums to the 3815 approved drugs and
formulations considered for this study. With the example data in
Fig. 3, the positive likelihood, LR+, is 11.0, suggesting that if
arrhythmia is observed in a nonclinical study there is high likeli-
hood of observing it in human, 11 times that of observing it with-
out a nonclinical observation. The negative likelihood, LR-, is 0.95,
suggesting that the lack of observation of arrhythmia in nonclinical
studies only slightly lowers the likelihood of seeing it in clinicalTable 1
Subjective interpretation of likelihood ratios (Ref. [22]).
LR+ LR Interpretation
>10 <0.1 Large and often conclusive shifts in probability
5–10 0.1–0.2 Moderate shifts in probability
2–5 0.2–0.5 Small, but sometimes important, shifts in probability
1–2 0.5–1 Alters probability to a small, and rarely important, degreestudies. Analyses were carried out to examine the observations
grouped in various MedDRA classiﬁcations of events, as well as
for speciﬁc observations such as QT prolongation.
For prediction of drug withdrawal the same analyses were used,
however the categories used in the 2  2 table were ‘‘withdrawn’’
and ‘‘not withdrawn’’ on the horizontal access and ‘‘adverse event
observed’’ and ‘‘adverse event not observed’’ on the vertical access.
This was used to compute the likelihood ratio of withdrawal for
each drug/adverse event pair. As with the previous analysis only
relationships with greater than 95% conﬁdence as computed by
the Fisher’s exact test were retained.
2.3. Assumptions
Several important assumptions must be made about the unifor-
mity of the data. We assume that the dosages in regulatory sub-
missions for nonclinical adverse events are relevant to human
doses. This work does not compare dosing or plasma concentration
between nonclinical and clinical studies.
The reports of nonclinical toxicity are assumed to be only the
‘signiﬁcant’ reports. That is they have been curated by the medical
team to remove events caused by very high doses in safety studies.
The assumption is that since these were successful clinical trials
the animal and human doses reported are both relevant for the
studies undertaken.
We also assume that the patient safety plan is monitoring for
expected events; however, some unexpected events may not be
monitored. These idiosyncratic events may be the cause of with-
drawal or drug failure and could skew the statistics.3. Results and discussion
3.1. Limitations and assumptions
3.1.1. Limitations
There are many issues complicating a statistical study of this
nature. While it provides some guidance for the risks for clinical
trials associated with nonclinical observations, some limitations
must be noted.
The drugs represented in regulatory approval data are not a ran-
dom sample. They represent the culmination of a long elimination
process. Drugs with serious nonclinical events have been elimi-
nated. Drugs with serious clinical events have also been eliminated
due to discontinued trials and withdrawal of applications and that
data is not available from regulatory documents. This process has
removed many ‘‘true positive’’ signals from the statistics.
However, at the same time it may have removed ‘‘false positive’’
drugs abandoned due to caution from animal effects that would
not be observed in humans. In general the statistical conclusions
here may not apply to preclinical compounds. These risk factors
Table 3
Likelihood of a cardiac clinical observation given the nonclinical observation.
Event Sensitivity Speciﬁcity LR+ LR
Arrhythmia 0.05 1.00 11.04 0.95
Electrocardiogram QT prolonged 0.15 0.99 10.70 0.86
Ventricular arrhythmias and
cardiac arrest
0.06 0.99 7.22 0.95
Supraventricular arrhythmias 0.04 0.99 6.84 0.97
Vascular hypertensive disorders
NEC
0.01 1.00 3.09 0.99
Table 4
Likelihood of a liver related clinical observation given the nonclinical observation.
Event Sensitivity Speciﬁcity LR+ LR
Hepatic function abnormal 0.01 1.00 25.63 0.99
Blood bilirubin increased 0.20 0.97 7.08 0.82
Aspartate aminotransferase 0.27 0.96 6.42 0.76
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clinical trials.
The lack of data on the degree of the reported events is also a
limitation of this analysis. A given clinical event could be of a
minor or devastating degree. This limitation is ameliorated some-
what by the hope that the set of approved drugs has removed pro-
found adverse events, and that only medically meaningful events
are reported in approval documents.
The major reasons for drug withdrawal, or relabeling, are liver
and cardiovascular issues, as shown in Table 2. Therefore develop-
ment teams focus on these areas as possible roadblocks in the
development process. This focus may increase the statistical relia-
bility of these nonclinical–clinical relationships over the other less
common issues. This work did not systematically measure the sta-
tistical signiﬁcance of all possible observations. A more inclusive
study may result in discovery of stronger markers for clinical trial
risk factors.increased
Alanine aminotransferase increased 0.47 0.93 6.29 0.57
Jaundice 0.01 1.00 5.13 0.99
Blood alkaline phosphatase
increased
0.39 0.92 5.05 0.66
Hepatic necrosis 0.25 0.92 3.07 0.81
Hepatocellular damage and
hepatitis NEC
0.26 0.91 2.98 0.81
Liver disorder 0.53 0.81 2.86 0.57
Hepatitis 0.04 0.98 2.16 0.98
Table 5
Likelihood of a kidney related clinical observation given the nonclinical observation.
Event Sensitivity Speciﬁcity LR+ LR
Blood creatinine increased 0.19 0.97 7.57 0.83
Renal failure and impairment 0.05 0.99 4.29 0.96
Nephropathies 0.35 0.88 2.98 0.73
Table 63.2. Predictive relationship of nonclinical to clinical adverse events
The statistical analysis comparing adverse event observations in
nonclinical and clinical studies is presented in Tables 3–5.
Statistical analysis relating either nonclinical or clinical observa-
tions to drug withdrawal are shown in Tables 6 and 7. In this study
the statistics all but one category includes over three thousand
compounds, as compared to the 150 compounds considered in
the Olson study. Negative likelihood, the ability to predict that if
an observation is not made in a nonclinical study, it will not be
observed in clinical studies provides the probability of ‘‘safety’’
for that observation. Positive likelihood is a prediction that if the
observation is made in a nonclinical study, it will appear in a
human clinical study. The relationships are not generally symmet-
ric; one often observes that a high LR+ is not paired with a low
LR; meaning that the presence of a nonclinical observation may
be strongly related to high risk in humans, but the lack of the same
nonclinical observation does not generally imply safety in humans.Likelihood of drug withdrawal given cardiac related clinical or nonclinical
observations.
Event Category LR+ LR
Arrhythmia Preclinical 11.80 0.83
Electrocardiogram QT prolonged Preclinical 8.94 0.80
Ventricular arrhythmias and cardiac arrest Preclinical 8.44 0.87
C-reactive protein increased Clinical 6.84 0.94
Supraventricular arrhythmias Preclinical 5.76 0.95
Electrocardiogram QT prolonged Clinical 5.32 0.55
Supraventricular arrhythmias Clinical 3.22 0.52
Arrhythmia Clinical 3.13 0.27
Ventricular arrhythmias and cardiac arrest Clinical 2.58 0.53
Vascular hypertensive disorders NEC Clinical 2.54 0.363.2.1. Cardiac issues
The results for cardiac issues are presented in Table 3. Long QT
is a biomarker for a rare but potentially fatal ventricular arrhyth-
mia – Torsades de pointes [25]. Therefore, there is a substantial
effort in the early drug development process to detect drug-in-
duced QT prolongation using appropriate animal models and accu-
rately predict the risk of long QT Interval in humans.
In this analysis, the likelihood ratio for observing QT elongation
in human, if observed in nonclinical models is 10.70, which suggest
that observation of QT elongation in nonclinical studies predicts
substantial human risk. The negative concordance, also of highTable 2
The top 14 systems affected by adverse reactions to 284 drugs withdrawn or
relabeled since 1969 (Ref. [24]).
System affected by adverse drug reaction Number of drugs affected (%)
Liver 74 (16)
Cardiovascular 40 (8.7)
Hematologic 39 (8.5)
Nervous system 36 (7.9)
Skin 34 (7.4)
Tumorigenicity 28 (6.1)
Urinary tract 28 (6.1)
Immunologic 27 (5.9)
Drug abuse 23 (5.0)
Psychiatric 17 (3.7)
Sensory systems 15 (3.3)
Gastrointestinal 12 (2.6)
Drug–drug interactions 11 (2.4)
Respiratory 11 (2.4)interest, is 0.86. This value suggests that the lack of observation
of QT prolongation in nonclinical studies does not inform one of
the risks to human (based on statistics from this data). This is
because there are 319 drugs where QT prolongation is observed
in clinical studies without a nonclinical observation. Summing
the count of drugs with any adverse event in the more inclusive
MedDRA category of arrhythmia provides a similar statistic with
a signiﬁcant likelihood ratio of 5.84.
In general, the lack of a cardiac nonclinical observation does not
appear to reduce the risk of it appearing in a clinical study. For
example even though nonclinical observation of arrhythmia
increases risk by a factor of 11, the lack of seeing arrhythmia unfor-
tunately has no statistical implication for safety in humans in this
data set because the LR value is close to 1.0, at 0.95.
Table 3 also illustrates the difference between LR and sensitiv-
ity/speciﬁcity. For each item the sensitivity value is quite low,
Table 7
Likelihood of drug withdrawal given liver related clinical or nonclinical observations.
Event Category LR+ LR
Hepatic necrosis Clinical 6.93 0.67
Hepatitis Clinical 4.51 0.34
Jaundice Clinical 4.17 0.35
Hepatic function abnormal Clinical 3.52 0.76
Blood bilirubin increased Clinical 3.52 0.54
Blood alkaline phosphatase increased Preclinical 3.46 0.64
Hepatic necrosis Preclinical 3.42 0.76
Blood alkaline phosphatase increased Clinical 3.41 0.51
Alanine aminotransferase increased Preclinical 3.33 0.57
Alanine aminotransferase increased Clinical 3.03 0.44
Aspartate aminotransferase increased Clinical 2.96 0.45
Hepatocellular damage and hepatitis NEC Clinical 2.91 0.31
Blood bilirubin increased Preclinical 2.81 0.90
Liver disorder Clinical 2.71 0.88
Liver disorder Preclinical 2.48 0.62
Hepatocellular damage and hepatitis NEC Preclinical 2.00 0.84
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predictive value. The reason is that the overall prevalence of these
events is low in clinical trials; only 56 drugs out of the 3815 are
’true positives’ (have both nonclinical and clinical observations)
for QT elongation, and only 12 for vascular hypertensive disorders.3.2.2. Liver issues
For the liver related observations shown in Table 4, nonclinical
observations in the class ‘‘Hepatic function abnormal’’ imply sig-
niﬁcant risk of those observations in humans with a likelihood
ratio over 25.
Other nonclinical observations predictive for clinical observa-
tions include the markers alanine aminotransferase (ALAT) and
aspartate aminotransferase (ASP), with positive likelihood ratio of
6.29 and 6.42. Unlike most liver observations, the lack of elevated
ALAT results in a small decrease of risk of its observation in clinical
studies. These statistics appears to vindicate the widespread use of
ALAT and ASP as nonclinical biomarkers for liver issues in human.
The same is true for bilirubin; if increased bilirubin is observed inTable 8
Sample computation of total risk based on product of risk factors for trovaﬂoxacin.
Event Event category LR+
Gastrointestinal ulceration and perforation Preclinical 4.49
Gastrointestinal ulceration and perforation Clinical 3.46
Anemia Preclinical 4.53
Cerebrovascular accident Clinical 3.69
Blood creatinine increased Preclinical 3.05
Nephropathies Preclinical 3.03
Nephropathies Clinical 3.38
Renal failure and impairment Preclinical 3.26
Injection and infusion site reactions Preclinical 3.60
C-reactive protein increased Clinical 6.84
Ventricular arrhythmias and cardiac arrest Preclinical 8.44
Supraventricular arrhythmias Preclinical 5.76
Supraventricular arrhythmias Clinical 3.22
Arrhythmia Preclinical 11.80
Arrhythmia Clinical 3.13
Electrocardiogram QT prolonged Preclinical 8.94
Electrocardiogram QT prolonged Clinical 5.32
Hepatic function abnormal Clinical 3.52
Hepatitis Clinical 4.51
Jaundice Clinical 4.17
Blood bilirubin increased Clinical 3.52
Hepatic necrosis Preclinical 3.42
Hepatic necrosis Clinical 6.93
Blood alkaline phosphatase increased Preclinical 3.46
Blood alkaline phosphatase increased Clinical 3.41
Alanine aminotransferase increased Preclinical 3.33
Alanine aminotransferase increased Clinical 3.03animals for a given drug, the likelihood of it being observed in a
clinical study is increased by 7.
Table 5 shows that for general nephropathy and other renal dis-
orders, there is little statistical risk change due to a nonclinical
observation, or lack of observation. The exception is increased
creatinine, which increases the likelihood of a clinical observation
by 7 times if observed in nonclinical study.
3.3. Predictive relationship of adverse events to drug withdrawal from
market
Another metric of interest to the drug development process is
the ability to identify speciﬁc observations as markers for either
drug failure or drug withdrawal. Regulatory documents are not
available for non-approved submissions, but 102 approved drugs
have been withdrawn due to adverse events.
Table 6 shows statistics computed relating either clinical or
nonclinical cardiac-related observations to drug withdrawal. The
high likelihood of withdrawal if QT prolongation is observed is
not surprising; many of the withdrawn drugs in this analysis were
withdrawn speciﬁcally because of this effect. It is interesting that
the nonclinical observation suggests more risk of withdrawal than
the clinical, but this may also be the result of observational bias.
The same is true of nonclinical arrhythmia observations; they sug-
gest a mild increase in risk of withdrawal, where the clinical obser-
vation does not. The last interesting point is the low negative
likelihood of withdrawal associated with lack of arrhythmia obser-
vations in clinical studies (0.27). Thus the lack of this observation
statistically decreases the risk of drug failure.
Table 7 suggests that the lack of any hepatitis or jaundice obser-
vations in clinical studies lowers the risk of failure or withdrawal
by a factor of 2.
3.4. Assessing the overall risk of drug withdrawal from market
Given the ability to compute likelihood of withdrawal based on
adverse event observations, one can evaluate a drug’s chance of
withdrawal by taking the product of withdrawal risk for eachLR Observed (+) or Not observed () Resulting risk factor
0.70 + 4.49
0.54  0.54
0.86  0.86
0.62  0.62
0.88 + 3.05
0.64  0.64
0.57 + 3.38
0.95  0.95
0.75  0.75
0.94  0.94
0.87 + 8.44
0.95  0.95
0.52  0.52
0.83  0.83
0.27 + 3.13
0.80  0.80
0.55 + 5.32
0.76 + 3.52
0.34  0.34
0.35  0.35
0.54  0.54
0.76 + 3.42
0.67 + 6.93
0.64  0.64
0.51  0.51
0.57  0.57
0.44 + 3.03
Risk product 801.47
Table 9
Sample computation of total risk based on product of risk factors for hydrochlorothiazide.
Event Event category LR+ LR Test result Resulting risk factor
Gastrointestinal ulceration and perforation Preclinical 4.49 0.70  0.70
Gastrointestinal ulceration and perforation Clinical 3.46 0.54  0.54
Anaemia Preclinical 4.53 0.86  0.86
Cerebrovascular accident Clinical 3.69 0.62  0.62
Blood creatinine increased Preclinical 3.05 0.88  0.88
Nephropathies Preclinical 3.03 0.64  0.64
Nephropathies Clinical 3.38 0.57  0.57
Renal failure and impairment Preclinical 3.26 0.95  0.95
Injection and infusion site reactions Preclinical 3.60 0.75  0.75
C-reactive protein increased Clinical 6.84 0.94  0.94
Ventricular arrhythmias and cardiac arrest Preclinical 8.44 0.87  0.87
Supraventricular arrhythmias Preclinical 5.76 0.95  0.95
Supraventricular arrhythmias Clinical 3.22 0.52  0.52
Arrhythmia Preclinical 11.80 0.83  0.83
Arrhythmia Clinical 3.13 0.27 + 3.13
Electrocardiogram QT prolonged Preclinical 8.94 0.80  0.80
Electrocardiogram QT prolonged Clinical 5.32 0.55  0.55
Hepatic function abnormal Clinical 3.52 0.76  0.76
Hepatitis Clinical 4.51 0.34  0.34
Jaundice Clinical 4.17 0.35  0.35
Blood bilirubin increased Clinical 3.52 0.54  0.54
Hepatic necrosis Preclinical 3.42 0.76  0.76
Hepatic necrosis Clinical 6.93 0.67  0.67
Blood alkaline phosphatase increased Preclinical 3.46 0.64  0.64
Blood alkaline phosphatase increased Clinical 3.41 0.51  0.51
Alanine aminotransferase increased Preclinical 3.33 0.57  0.57
Alanine aminotransferase increased Clinical 3.03 0.44  0.44
Risk product 0.00004
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hydrochlorothiazide are compared. While hydrochlorothiazide is
well tolerated, the use of trovaﬂoxacin has been restricted due to
liver toxicity [26].
Table 8 shows an example computation of total risk for the drug
trovaﬂoxacin based on the Bayesian statistics and the risk factors
associated with the observation, or lack of observation of sta-
tistically signiﬁcant events (those with positive likelihood ratios,
LR+, greater than 3.0). If the observation is made, the resulting risk
factor is drawn from the LR+ column, the positive likelihood. If the
observation is not made the risk factor is drawn from the LR col-
umn, the negative likelihood. The total risk is the product of these
factors. This analysis computes the likelihood of failure of trova-
ﬂoxacin to be over 800. That is, this drug is 800 times more likely
to fail than the ‘‘typical’’ approved drug. In contrast, Table 9 shows
the risk factor for hydochlorothiazide, a drug with comparatively
few serious reported adverse events. The computed risk factor for
hydrochlorothiazide is 0.00004. To extend this work one could
compute this value over all events for all drugs to create a baseline
for evaluation of ongoing clinical programs.
The advantage of the likelihood ratio over the positive predic-
tive value is that it can be used to evaluate drug classes to give
an accurate probability of withdrawal. For example, the prevalence
of withdrawal among the ﬂuoroquinolone antibiotics is 0.25 (4
withdrawn of 16 approved), or odds of 1 in 3 (0.25/(1  0.25)).
The odds of withdrawal of a ﬂuoroquinolone antibiotic, if QT elon-
gation is seen in a preclinical study, is the pretest odds times the
likelihood ratio, 8.94 ⁄ 0.333, or 2.98. This is close to 3–1 odds of
being withdrawn, which is equivalent to a probability of 0.75
(3/(3 + 1)) – far greater than the initial probability of 0.25 – if QT
elongation is observed in a nonclinical study of a drug in this class.
4. Conclusions
In this study we proposed a framework based on likelihood
ratio computed using 2  2 contingency matrices for studying
the relationship between nonclinical and clinical adverse eventsin order to create robust analyses to understand the implications
of nonclinical adverse events to clinically observed adverse events.
The framework was also used to understand the implication of
various nonclinical and clinical adverse events for drug
withdrawal.
From this study we learned that some adverse events observed
in nonclinical studies are strongly associated with the observation
in corresponding clinical studies. For example nonclinical observa-
tion of cardiac arrhythmia and QT interval prolongation is strongly
suggestive that it will be observed in clinical studies. Others, such
as hepatitis, are far less strongly associated and many more. such
as cholestasis, do not have statistically signiﬁcant relationships
between nonclinical and clinical observations. While observation
of many nonclinical adverse events appear to be related to a high
risk of seeing the same event in humans, little statistical inference
for clinical results could be made for most cases when a particular
adverse event was not observed.
In addition analysis of the relationship between both nonclini-
cal and clinical adverse events and drug withdrawal showed that
some adverse events are much more strongly associated with drug
withdrawal than others, particularly arrhythmias and hepatic
necrosis. The idea of using the product of the individual risk factors
as an overall metric was tested on hydrochlorothiazide and trova-
ﬂoxacin and for those two cases the product was consistent with
the known safety of the ﬁrst, and withdrawal of the latter drug.
The concept of using the product of the individual risk factors for
withdrawal as an overall metric was tested on hydrochlorothiazide
and trovaﬂoxacin and for those two cases the product was consis-
tent with the known safety of the ﬁrst, and withdrawal of the latter
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